DOCSLIB.ORG

Use of High Risk Medications in the Elderly (DAE)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Use of High Risk Medications in the Elderly (DAE) Use of High Risk Medications in the Elderly (DAE) Contents OVERVIEW ................................................................................................................................................. 1 TECHNICAL SPECIFICATIONS ...................................................................................................................... 3 APPENDIX 1 ................................................................................................................................................ 5 OVERVIEW Measure Description The percentage of patients 65 years of age and older who received at least one high-risk medication. The percentage of patients 65 years of age and older who received at least two different high-risk medications. Deviations from HEDIS Specifications The denominator from the third-party specifications includes beneficiaries who have “continuous medical and pharmacy benefit enrollment for the measurement year with no more than one gap in enrollment of up to 45 days during the measurement year. The patient must be enrolled as of December 31 of the measurement year.” The common enrollment specifications (and exclusion of 2010 part year beneficiaries) mean that all beneficiaries in the denominator will have enrollment for all of 2010. Also, the allowed gap of 45 days for HEDIS specs is different from the one-month gap allowed in our specs. The third-party specifications do not specify the setting for the NDC codes, but there are no NDC codes on claims other than Part D so we will only be searching in Part D claims. Assumptions/Notes The eligible population for this measure is based on discharges, not patients. This differs from how the eligible population is defined for other performance measures. It is possible for the denominator to contain multiple discharge records for the same individual. Data Sources Denominator inclusion data: 2010 Part A file 2010 Part B file 2010 Part D file Denominator exclusion data: None Numerator inclusion data: 2010 Part D file 1 Denominator Beneficiaries are included in the denominator if the following criteria are met: 65 years and older as of December 31 of the measurement year Continuous medical and pharmacy benefit enrollment for the measurement year with no more than one gap in enrollment of up to 45 days during the measurement year Enrolled as of December 31 of the measurement Denominator Exclusions None Numerator Beneficiaries are included if the beneficiary meets the following criteria: Numerator 1: At least one prescription dispensed for any high-risk medication during the measurement year. Numerator 2: At least two prescriptions dispensed for different high-risk medications during the measurement year. Rate Calculations For both rates, a lower rate represents better performance. 2 TECHNICAL SPECIFICATIONS Denominator The eligible population of beneficiaries who were a) 65 years and older as of December 31 of the measurement year and b) have continuous medical and pharmacy benefit enrollment for the measurement year with no more than one gap in enrollment of up to 45 days during the measurement year. Note that the patient must be enrolled as of December 31 of the measurement year. A. For each beneficiaryi attributed to providerk use the enrollment arrays created in the enrollment pre- processing program and create NCQA_HRME_DENi = 1 if: 1. 65 <= Years between BENE_DOB and 12/31/2010 and The sum of the Part A, B, and D enrollment flags in each month of 2010 is less than 3 in no more than one month. The sum of the flags in December 2010 must be equal to 3. Denominator Exclusions None. Numerator Numerator 1 - At least one prescription dispensed for any high-risk medication (Table DAE-A) during the measurement year. Identify different drugs using the Drug ID field located in the NDC list on NCQA’s Web site (www.ncqa.org). NCQA provided a comprehensive list of medications and NDC codes to www.ncqa.org on November 15, 2010. Please see the Excel file Table DAE-A - Use of High-Risk Medications in the Elderly (DAE).xls for the list of NDCs to use. A. For each beneficiary i, create NCQA_HRME1_NUMi variable B. Search the 2010 Part D File and flag beneficiaries for inclusion in the numerator. 1. NCQA_HRME1_NUMi = 1 if 2. At least one of the following occurred between 1/1/2010 and 12/31/2010 for beneficiaryi in the 2010 Part D File where NCQA_HRME_DENi = 1: Description Variable Values/Rule Label Name (Unless otherwise noted, only require one {n} to equal the value) NDC Product service ID: High-Risk Medications – DAE_IIB2_NDC_A_11 short sas name = See Appendix 1 DAE_IIB2_NDC_B_11 PRDSRVID, long sas DAE_IIB2_NDC_C_11 name = PROD_SRVC_ID C. Else NCQA_HRME1_NUMi = 0 3 Numerator 2 - At least two prescriptions dispensed for different high-risk medications (Table DAE-A) during the measurement year. D. For each beneficiary i, create NCQA_HRME2_NUMi variable E. Search the 2010 Part D File and flag beneficiaries for inclusion in the numerator. 1. NCQA_HRME2_NUMi = 1 if 2. At least two of the following occurred between 1/1/2010 and 12/31/2010 for beneficiaryi in the 2010 Part D File where NCQA_HRME_DENi = 1: Description Variable Values/Rule (Unless otherwise noted, only require one Name {n} to equal the value) NDC Product service ID: High-Risk Medications – See Appendix 1 short sas name = PRDSRVID, long sas name = PROD_SRVC_ID Else NCQA_HRME2_NUMi = 0 Provider Performance Measure A. For each providerk, create NCQA_HRME1_RATEk = (∑NCQA_HRME1_NUMi/∑NCQA_HRME1_DENi)*100 B. For each providerk, create NCQA_HRME2_RATEk = (∑NCQA_HRME2_NUMi/∑NCQA_HRME2_DENi)*100 4 APPENDIX 1 Use of High Risk Medications in the Elderly (DAE) Numerator Beneficiaries from the 2010 Part D file with at least one prescription for a high-risk medication: NDC Codes 00002035302 propoxyphene napsylate 100 mg oral tablet 00002035303 propoxyphene napsylate 100 mg oral tablet 00002035333 propoxyphene napsylate 100 mg oral tablet 00002080302 propoxyphene hydrochloride 65 mg oral capsule 00002080303 propoxyphene hydrochloride 65 mg oral capsule 00002080333 propoxyphene hydrochloride 65 mg oral capsule 00002311102 ASA/caffeine/propoxyphene 389 mg-32.4 mg-65 mg oral capsule 00002311103 ASA/caffeine/propoxyphene 389 mg-32.4 mg-65 mg oral capsule 00006006268 cyproheptadine 4 mg oral tablet 00006093128 cyclobenzaprine 10 mg oral tablet 00007351220 dextroamphetamine 5 mg oral capsule, extended release 00007351259 dextroamphetamine 5 mg oral capsule, extended release 00007351320 dextroamphetamine 10 mg oral capsule, extended release 00007351359 dextroamphetamine 10 mg oral capsule, extended release 00007351420 dextroamphetamine 15 mg oral capsule, extended release 00007351459 dextroamphetamine 15 mg oral capsule, extended release 00007351920 dextroamphetamine 5 mg oral tablet 00008002702 promethazine 25 mg oral tablet 00008025901 meperidine 100 mg/mL injectable solution 00009002401 benzphetamine 50 mg oral tablet 00009002402 benzphetamine 50 mg oral tablet 00009377201 estropipate 0.75 mg oral tablet 00009377301 estropipate 1.5 mg oral tablet 00009377401 estropipate 3 mg oral tablet 00009377417 estropipate 3 mg oral tablet 00024033206 meperidine 50 mg/5 mL oral syrup 00024033502 meperidine 50 mg oral tablet 00024033504 meperidine 50 mg oral tablet 00024033506 meperidine 50 mg oral tablet 00024033704 meperidine 100 mg oral tablet 00024193704 acetaminophen-pentazocine 650 mg-25 mg oral tablet 00024195104 naloxone-pentazocine 0.5 mg-50 mg oral tablet 5 00025006131 atropine-diphenoxylate 0.025 mg-2.5 mg oral tablet 00025006151 atropine-diphenoxylate 0.025 mg-2.5 mg oral tablet 00025006152 atropine-diphenoxylate 0.025 mg-2.5 mg oral tablet 00025006155 atropine-diphenoxylate 0.025 mg-2.5 mg oral tablet 00025006602 atropine-diphenoxylate 0.025 mg-2.5 mg/5 mL oral liquid 00029280030 esterified estrogens 0.3 mg oral tablet 00031224713 diphenhydrAMINE-phenylephrine 6.25 mg-2.5 mg/5 mL oral liquid 00031742963 methocarbamol 500 mg oral tablet 00031744963 methocarbamol 750 mg oral tablet 00031744970 methocarbamol 750 mg oral tablet 00031869812 diphenhydrAMINE-phenylephrine 6.25 mg-2.5 mg/5 mL oral liquid 00031869813 diphenhydrAMINE-phenylephrine 6.25 mg-2.5 mg/5 mL oral liquid 00031870112 diphenhydrAMINE-phenylephrine 6.25 mg-2.5 mg/5 mL oral liquid 00031871512 diphenhydrAMINE-phenylephrine 6.25 mg-2.5 mg/5 mL oral liquid esterified estrogens-methylTESTOSTERone 0.625 mg-1.25 mg oral 00032102301 tablet esterified estrogens-methylTESTOSTERone 1.25 mg-2.5 mg oral 00032102601 tablet esterified estrogens-methylTESTOSTERone 1.25 mg-2.5 mg oral 00032102610 tablet 00037011016 butabarbital 30 mg/5 mL oral elixir 00037011360 butabarbital 30 mg oral tablet 00037011380 butabarbital 30 mg oral tablet 00037011460 butabarbital 50 mg oral tablet atropine/hyoscyamine/PB/scopolamine 0.0194 mg-0.1037 mg- 00037030192 16.2 mg-0.0065 mg oral tablet 00037200101 carisoprodol 350 mg oral tablet 00037200103 carisoprodol 350 mg oral tablet 00037210301 aspirin-carisoprodol 325 mg-200 mg oral tablet 00037225010 carisoprodol 250 mg oral tablet 00037225030 carisoprodol 250 mg oral tablet 00037240301 ASA/carisoprodol/codeine oral tablet APAP/diphenhydrAMINE/phenylephrine 325 mg-12.5 mg-5 mg/15 00043046008 mL oral syrup diphenhydrAMINE-phenylephrine 6.25 mg-6.25 mg/5 mL oral 00043620404 liquid diphenhydrAMINE-phenylephrine 6.25 mg-6.25 mg/5 mL oral 00043620408 liquid APAP/diphenhydrAMINE/phenylephrine 650 mg-25 mg-10 mg oral 00043625606 powder for reconstitution APAP/diphenhydrAMINE/phenylephrine 325 mg-12.5 mg-5 mg/15 00043626508 mL oral syrup 00045018210 acetaminophen-diphenhydrAMINE
Load more

Recommended publications
  • Potentially Harmful Drugs in the Elderly: Beers List
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− March 2019 ~ Resource #350301 Potentially Harmful Drugs in the Elderly: Beers List In 1991, Dr. Mark Beers and colleagues published a methods paper describing the development of a consensus list of medicines considered to be inappropriate for long-term care facility residents.12 The “Beers list” is now in its sixth permutation.1 It is intended for use by clinicians in outpatient as well as inpatient settings (but not hospice or palliative care) to improve the care of patients 65 years of age and older.1 It includes medications that should generally be avoided in all elderly, used with caution, or used with caution or avoided in certain elderly.1 There is also a list of potentially harmful drug-drug interactions in seniors, as well as a list of medications that may need to be avoided or have their dosage reduced based on renal function.1 This information is not comprehensive; medications and interactions were chosen for inclusion based on potential harm in relation to benefit in the elderly, and availability of alternatives with a more favorable risk/benefit ratio.1 The criteria no longer address drugs to avoid in patients with seizures or insomnia because these concerns are not unique to the elderly.1 Another notable deletion is H2 blockers as a concern in dementia; evidence of cognitive impairment is weak, and long-term PPIs pose risks.1 Glimepiride has been added as a drug to avoid. Some drugs have been added with cautions (dextromethorphan/quinidine, trimethoprim/sulfamethoxazole), and some have had cautions added (rivaroxaban, tramadol, SNRIs).
    [Show full text]
  • Randomized Controlled Pilot Trial of Cabergoline, Hydergine and Levodopa/Carbidopa: Los Angeles Cocaine Rapid Efficacy Screening
    Blackwell Science, LtdOxford, UKADDAddiction1359-6357© 2005 Society for the Study of Addiction 100•••• Original Article Cabergoline, hydergine, levodopa/carbidopa Steven Shoptaw et al. RESEARCH REPORT Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST) Steven Shoptaw1, Donnie W. Watson2, Chris Reiber1, Richard A. Rawson1, Margaret A. Montgomery3, Maria D. Majewska3 & Walter Ling1 UCLA Integrated Substance Abuse Programs, Los Angeles, CA1 , Friends Research Institute, Inc., Los Angeles, CA2 and National Institute on Drug Abuse, Division of Treatment Research and Development, Bethesda, MD, USA3 Correspondence to: ABSTRACT Steven Shoptaw PhD UCLA/Integrated Substance Abuse Programs Aim This study tested three dopaminergic medications against a common 11075 Santa Monica Blvd unmatched placebo condition: hydergine 1 mg three times daily (n = 15); Suite 200 levodopa/carbidopa 25/100 mg three times daily (n = 15); cabergoline 0.5 mg Los Angeles per week (n = 15); and placebo three times daily (n = 15) as potential pharma- CA 90025 USA cotherapies for cocaine dependence. E-mail: [email protected] Design The four-parallel group, Cocaine Rapid Efficacy Screening Trial (CREST) design featured a 2-week baseline period followed by randomization to an 8-week medication condition that included 1 hour per week of cognitive RESEARCH REPORT behavioral drug counseling. A safety evaluation was conducted 4 weeks after termination. Measures Outcomes included cocaine metabolites measured in urine, reten- tion and self-reports for drug use, cocaine craving, clinical improvement, mood and HIV risk behaviors. Results Participants assigned to receive cabergoline provided more urine sam- ples negative for cocaine metabolites (42.4%) than those assigned to receive pla- cebo (25.0%), a statistically significant difference after controlling for baseline differences in self-reported cocaine use (F = 2.95, df = 3; P = 0.05).
    [Show full text]
  • Albert Hofmann's Pioneering Work on Ergot Alkaloids and Its Impact On
    BIRTHDAY 83 CHIMIA 2006, 60, No. 1/2 Chimia 60 (2006) 83–87 © Schweizerische Chemische Gesellschaft ISSN 0009–4293 Albert Hofmann’s Pioneering Work on Ergot Alkaloids and Its Impact on the Search of Novel Drugs at Sandoz, a Predecessor Company of Novartis Dedicated to Dr. Albert Hofmann on the occasion of his 100th birthday Rudolf K.A. Giger* and Günter Engela Abstract: The scientific research on ergot alkaloids is fundamentally related to the work of Dr. Albert Hofmann, who was able to produce, from 1935 onwards, a number of novel and valuable drugs, some of which are still in use today. The complex chemical structures of ergot peptide alkaloids and their pluripotent pharmacological activity were a great challenge for Dr. Hofmann and his associates who sought to unravel the secrets of the ergot peptide alkaloids; a source of inspiration for the design of novel, selective and valuable medicines. Keywords: Aminocyclole · Bromocriptine Parlodel® · Dihydroergotamine Dihydergot® · Dihydro ergot peptide alkaloids · Ergobasin/ergometrin · Ergocornine · Ergocristine · α- and β-Ergocryptine · Ergolene · Ergoline · Ergoloid mesylate Hydergine® · Ergotamine Gynergen® · Ergotoxine · Lisuride · Lysergic acid diethylamide LSD · Methylergometrine Methergine® · Methysergide Deseril® · Paspalic acid · Pindolol Visken® · Psilocybin · Serotonin · Tegaserod Zelmac®/Zelnorm® · Tropisetron Navoban® Fig. 1. Albert Hofmann in 1943, 1979 and 2001 (Photos in 2001 taken by J. Zadrobilek and P. Schmetz) Dr. Albert Hofmann (Fig. 1), born on From the ‘Ergot Poison’ to *Correspondence: Dr. R.K.A. Giger January 11, 1906, started his extremely Ergotamine Novartis Pharma AG NIBR Global Discovery Chemistry successful career in 1929 at Sandoz Phar- Lead Synthesis & Chemogenetics ma in the chemical department directed The scientific research on ergot alka- WSJ-507.5.51 by Prof.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Conditions, Impairments Or Considerations That Would Disqualify a Proposed Insured from Approval
    Nationwide YourLife CareMatters® Prequalification guide Conditions, impairments or considerations that would disqualify a proposed insured from approval In rare instances, there may be a history indicated for disqualification in this guide that you feel may qualify for a CareMatters® policy. These histories should be prescreened before an application is submitted. Histories not found in this prequalification guide will be given individual consideration. If you feel a history may be borderline for life and long-term care, please complete a prescreen with a CareMatters underwriter prior to submission of an application. For prescreens, call 1-855-381-5729. Include the prescreen reference number in the "Special Instructions Section" of the application, or prescreen via email at CMScreen@nationwide. com. Include a copy of the prescreen email reply with the application. The proposed insured must be a U.S. citizen or permanent green card holder (issued for 10 years or more) and be able to provide a copy of green card and Social Security/tax identification number card. Within the last five years, proposed insured has had, has been diagnosed as having or has been treated for: • Alcohol abuse or dependency • Cardiomyopathy • HIV positive, AIDS, ARC, severe • Paralysis, hemiplegia, paraplegia or • Cerebral palsy combined immunodeficiency, quadriplegia (excluding Bell's palsy) • Alzheimer's, dementia, senility, mild common variable immune • Cirrhosis of the liver • Parkinson's disease cognitive impairment (MCI), organic deficiency brain syndrome,
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Ergot Alkaloids: a Review on Therapeutic Applications
    European Journal of Medicinal Plants 14(3): 1-17, 2016, Article no.EJMP.25975 ISSN: 2231-0894, NLM ID: 101583475 SCIENCEDOMAIN international www.sciencedomain.org Ergot Alkaloids: A Review on Therapeutic Applications Niti Sharma 1* , Vinay K. Sharma 1, Hemanth Kumar Manikyam 1 1,2 and Acharya Bal Krishna 1Patanjali Natural Coloroma Pvt. Ltd, Haridwar, Uttarakhand - 249404, India. 2University of Patanjali, Haridwar, Uttarakhand - 249402, India. Authors’ contributions This work was carried out in collaboration between all authors. Authors NS and VKS designed the study, wrote the first draft of the manuscript. Authors ABK and HKM supervised the study. All authors read and approved the final manuscript. Article Information DOI: 10.9734/EJMP/2016/25975 Editor(s): (1) Marcello Iriti, Professor of Plant Biology and Pathology, Department of Agricultural and Environmental Sciences, Milan State University, Italy. Reviewers: (1) Nyoman Kertia, Gadjah Mada University, Indonesia. (2) Robert Perna, Texas Institute of Rehabilitation Research, Houston, TX, USA. (3) Charu Gupta, AIHRS, Amity University, UP, India. Complete Peer review History: http://sciencedomain.org/review-history/14283 Received 28 th March 2016 Accepted 12 th April 2016 Review Article st Published 21 April 2016 ABSTRACT Ergot of Rye is a plant disease caused by the fungus Claviceps purpurea which infects the grains of cereals and grasses but it is being used for ages for its medicinal properties. All the naturally obtained ergot alkaloids contain tetracyclic ergoline ring system, which makes them structurally similar with other neurotransmitters such as noradrenaline, dopamine or serotonin. Due to this structure homology these alkaloids can be used for the treatment of neuro related conditions like migraine, Parkinson’s disease etc.
    [Show full text]
  • Cover Next Page > Cover Next Page >
    cover next page > Cover title: The Psychopharmacology of Herbal Medicine : Plant Drugs That Alter Mind, Brain, and Behavior author: Spinella, Marcello. publisher: MIT Press isbn10 | asin: 0262692651 print isbn13: 9780262692656 ebook isbn13: 9780585386645 language: English subject Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. publication date: 2001 lcc: RC483.S65 2001eb ddc: 615/.788 subject: Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. cover next page > < previous page page_i next page > Page i The Psychopharmacology of Herbal Medicine < previous page page_i next page > cover next page > Cover title: The Psychopharmacology of Herbal Medicine : Plant Drugs That Alter Mind, Brain, and Behavior author: Spinella, Marcello. publisher: MIT Press isbn10 | asin: 0262692651 print isbn13: 9780262692656 ebook isbn13: 9780585386645 language: English subject Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. publication date: 2001 lcc: RC483.S65 2001eb ddc: 615/.788 subject: Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. cover next page > < previous page page_ii next page > Page ii This page intentionally left blank. < previous page page_ii next page > < previous page page_iii next page > Page iii The Psychopharmacology of Herbal Medicine Plant Drugs That Alter Mind, Brain, and Behavior Marcello Spinella < previous page page_iii next page > < previous page page_iv next page > Page iv © 2001 Massachusetts Institute of Technology All rights reserved. No part of this book may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from the publisher. This book was set in Adobe Sabon in QuarkXPress by Asco Typesetters, Hong Kong and was printed and bound in the United States of America.
    [Show full text]
  • August 2021 California Signaturevalue 4 Tier HMO Formulary
    Pharmacy | Formulary | California 2021 California SignatureValue 4-Tier HMO Formulary Please note: This Formulary is accurate as of August 1, 2021 and is subject to change after this date. All previous versions of this Formulary are no longer in effect. Your estimated coverage and copay/coinsurance may vary based on the benefit plan you choose and the effective date of the plan. This Formulary can also be accessed online at myuhc.com > Pharmacy Information > Prescription Drug Lists > California plans > SignatureValue HMO plans. Plan-specific coverage documents may be accessed online at uhc.com/statedruglists > Small Group Plans > California. If you are a UnitedHealthcare member, please register or log on to myuhc.com, or call the toll-free number on your health plan ID card to find pharmacy information specific to your benefit plan. This Formulary is applicable to the following health insurance products offered by UnitedHealthcare: • SignatureValue • SignatureValue Advantage • SignatureValue Alliance • SignatureValue Flex • SignatureValue Focus • SignatureValue Harmony • SignatureValue Performance Updated 6/17/2021 6/21 © 2021 United HealthCare Services, Inc. All Rights Reserved. WF3890815-N Contents At UnitedHealthcare, we want to help you better understand your medication options. ..................................................... 3 How do I use my Formulary? ............................................. 4 What are tiers? ........................................................ 5 When does the Formulary change? ........................................ 5 Utilization Management Programs ......................................... 6 Your Right to Request Access to a Non-formulary Drug ....................... 6 Requesting a Prior Authorization or Step Therapy Exception ................... 7 How do I locate and fill a prescription through a retail network pharmacy? . 7 How do I locate and fill a prescription through the mail order pharmacy? . 7 How do I locate and fill a prescription at a specialty pharmacy? ...............
    [Show full text]
  • Preferred Drug List
    Comprehensive PREFERRED DRUG LIST Buckeye Health Plan PAGE 1 Buckeye Health Plan Pharmacy Program Buckeye Health Plan, Inc. (Buckeye) is committed to providing appropriate, high quality, and cost effective drug therapy to all Buckeye members. Buckeye works with providers and pharmacists to ensure that medications used to treat a variety of conditions and diseases are covered. Buckeye covers prescription medications and certain over- the-counter (OTC) medications when ordered by a physician/clinician. The Pharmacy program covers all medically necessary Medicaid covered drugs. Some medications require prior authorization (PA) or have limitations on age, dosage, and maximum quantities. This section provides an overview of the Buckeye pharmacy program. For more detailed information, please visit our website at www.buckeyehealthplan.com. The following program covers both the Covered Families & Children (CFC) and Aged, Blind or Disabled (ABD) Ohio Medicaid consumers who are enrolled inBuckeye. Plan Preferred Drug List The Buckeye Preferred Drug List (PDL) describes the circumstances under which contracted pharmacy providers will be reimbursed for medications dispensed to members covered under the program. All drugs covered under the Ohio Medicaid program are available for Buckeye members. The PDL includes all drugs available without PA, drugs that require PA, and those agents that have the restrictions of Step Therapy (ST). The PDL applies to drugs you receive at retail pharmacies. The PDL is continually evaluated by the Buckeye Pharmacy and Therapeutics (P&T) Committee to promote the appropriate and cost-effective use of medications. The Committee is composed of the Buckeye Medical Director, Buckeye Pharmacy Director, Buckeye Clinical Pharmacists, and several Ohio primary care physicians, pharmacists, and specialists.
    [Show full text]
  • First-Generation Antihistamines (Medications Commonly Used To
    High­risk medication reference sheet The Pharmacy Quality Alliance has determined the following medications have the highest risk of side effects among those 65 years of age or older. “High­risk” means a medicine can cause serious health problems or accidents. High­risk medications can be: • A medicine that raises your risk of drowsiness, confusion, depression, organ damage, serious harm from a fall, or other dangerous side effects. • A medicine for one health problem that worsens another health problem. • Two or more medications that are dangerous when taken together. The more medicines you take, the greater the risk of negative interactions. Please review the list of high­risk medications below. If you are taking one or more of the medications listed, please speak with your doctor to determine if there are safer choices with fewer possible side effects. First­generation antihistamines (medications commonly used to treat allergies) • Brompheniramine • Cyproheptadine • Hydroxyzine • Carbinoxamine • Dexchlorpheniramine • Promethazine • Chlorpheniramine • Diphenhydramine (oral) • Triprolidine • Clemastine • Doxylamine Anti­Parkinson agents (to treat Parkinson’s disease) • Benztropine (oral) • Trihexyphenidyl Anti­thrombotics (medications used to prevent blood from clotting inappropriately) • Ticlopidine • Dipyridamole Anti­infective (medication used to treat infections) • Nitrofurantoin (only when taken for 90 days or more) Alpha blockers (medications that help blood vessels remain open) • Guanfacine • Reserpine (only if you take more than
    [Show full text]
  • High Risk Medication Alternative Table
    High Risk Medication Alternative Table Description High Risk Medication Rationale for risk* Alternatives Anticholinergics brompheniramine3, Highly anticholinergic, clearance Allergy: levocetirizine, desloratadine, montelukast, carbinoxamine3, reduced with advanced age, and azelastine, intranasal steroid (e.g., fluticasone4), OTCs chlorpheniramine3, tolerance develops when used as such as cetirizine, loratadine, fexofenadine, or clemastine3, cyproheptadine1, hypnotic; greater risk of confusion, dry intranasal normal saline (member to pay out of dexbrompheniramine3, mouth, constipation, and other pocket) dexchlorpheniramine3, anticholinergic effects and toxicity. Cough: OTCs such as guaifenesin, dextromethorphan diphenhydramine (oral)3, (member to pay out of pocket) dimenhydrinate3, Anti-emetic: ondansetron-oral1, granisetron-oral1, doxylamine3, hydroxyzine1, aprepitant-oral1 meclizine, promethazine1, triprolidine3 benztropine (oral)1, Not recommended for prevention of carbidopa & levodopa, carbidopa & levodopa & trihexyphenidyl1 extrapyramidal symptoms with entacapone, ropinirole, pramipexole, amantadine antipsychotics; more-effective agents available for treatment of Parkinson's disease. Antithrombotics dipyridamole - oral short May cause orthostatic hypotension; dipyridamole & aspirin4, clopidogrel acting1 (does not apply to ER more effective alternatives available; combination with aspirin) intravenous form acceptable for use in cardiac stress testing. Anti-infective nitrofurantoin Potential for pulmonary toxicity; safer For UTI Treatment,
    [Show full text]